Difficulty: Medium
Average Score: 68%
Practice
Carbidopa is unable to penetrate the blood-brain barrier it acts to reduce the peripheral conversion of levodopa to dopamine.
Correct answer
A
Rationale
Correct Answer: A
Rationale:
1. Carbidopa cannot cross the blood-brain barrier due to its large molecular size.
2. Carbidopa inhibits peripheral DOPA decarboxylase, preventing levodopa breakdown outside the brain.
3. By reducing peripheral levodopa conversion, carbidopa increases levodopa availability to cross the blood-brain barrier.
4. This results in more levodopa reaching the brain for conversion to dopamine, enhancing its central effects.
Summary:
- Choice A is true as carbidopa indeed prevents peripheral levodopa breakdown, enhancing its central effects.
- Choice B is incorrect because carbidopa does not act within the brain itself.
- Choice C is incorrect as there is a correct answer.
- Choice D is incorrect as not all statements are true.
Rationale:
1. Carbidopa cannot cross the blood-brain barrier due to its large molecular size.
2. Carbidopa inhibits peripheral DOPA decarboxylase, preventing levodopa breakdown outside the brain.
3. By reducing peripheral levodopa conversion, carbidopa increases levodopa availability to cross the blood-brain barrier.
4. This results in more levodopa reaching the brain for conversion to dopamine, enhancing its central effects.
Summary:
- Choice A is true as carbidopa indeed prevents peripheral levodopa breakdown, enhancing its central effects.
- Choice B is incorrect because carbidopa does not act within the brain itself.
- Choice C is incorrect as there is a correct answer.
- Choice D is incorrect as not all statements are true.